Modern medicine has enabled humans to mature into seniority, though our bodies and their demands change as we get older. Bellevue-based Viome Life Sciences wants to help people live longer, healthier lives. The company announced Tuesday a $67 million addition to its Series C funding round for its biotech solution. The raise brings Viome’s total funding to more than $150 million.
Led by Bold Capital Group, funds from this round will help Viome continue the development of its product pipeline. As a whole, Viome is a digital health platform focused on using nutrition to fuel health and longevity through its mRNA tech and AI-powered solution. The biotech side of the company works to address chronic diseases, cancer and aging.
Its solution was built in response to a gap Naveen Jain, Viome’s founder and CEO, saw within the current healthcare sector. About 60 percent of adult Americans have a chronic disease, as found by the National Association of Chronic Disease Directors. Such has created a significant need for early diagnostics tools and interventions that can help make a positive difference in individuals’ lives.
“The current healthcare industry is reactive and focused on managing symptoms of these chronic diseases, not preventing or curing them,” Jain told Built In via email. “Viome was founded upon the mission to understand and decode the complexity in each individual’s biochemistry — before the onset of life-impacting chronic conditions.”
Viome offers a suite of tools made for prevention, diagnosis and therapeutics for these conditions. It recently launched its first CancerDetect home test for oral and throat cancers that can detect early biomarkers associated with these cancers with 90 percent sensitivity and 95 percent specificity, according to the company.
The company’s new capital will go toward product development. It plans to introduce a new suite of wellness and diagnostic tests for the oral microbiome. It’s working on offerings such as an Oral Health Intelligence Test as well as early-detection diagnostic tests for elusive cancers and gastrointestinal disorders like IBD.
“Viome’s unique approach and unparalleled insight into the human microbiome and its interaction with the human host has helped nearly half a million individuals to take control of their health and address underlying causes of inflammation and microbial imbalance, both of which data strongly links to the development and onset of chronic disease,” Jain said. “With this funding, Viome will continue to focus on the research and development of early diagnostic tools for these life-altering illnesses and hard-to-detect cancers, while working to bring Viome’s science-backed products to new markets with the goal of benefiting millions more.”
This Series C extension comes nearly one year after Viome raised a $54 million pre-Series C round.
